Our mission is to revolutionise ADC development
ADCs represent a powerful addition to cancer treatment, with a mechanism that permits the delivery of potent cytotoxic agents directly to cancer cells using monoclonal antibodies that target tumour-specific antigens.
This selective approach to delivery of tumour killing payloads results in superior efficacy and fewer side effects for patients.
Antibodies: Fit-for-purpose antibodies with optimal ADC characteristicssourced through proprietary discovery or in-license opportunities
Bioconjugation: Proprietary bioconjugation technology for proven ADC stability
Linkers: Highly advanced tumor-selective cleavable peptide-based linkers
Building a robust pipeline to address tumour indications with high unmet medical need
*includes in-licensed payloads for multiple targets and proprietary payload series
Raising Therapeutic Index – solving the problem in the clinic
There are currently over 100 ADCs in the clinic, comprised of a selection of payload classes, numerous linkers and a wide range of antibodies, directed towards many distinct antigens.
Iksuda’s approach is straightforward – we create ADCs which incorporate multiple safety mechanisms for the targeted delivery of potent, next generation DNA damaging payloads for the treatment of the broadest patient population possible.
Improving therapeutic index